Group 1 - The core viewpoint of the news is that Tongda Co., Ltd. has shown significant trading activity and financial performance, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - On February 3, Tongda Co., Ltd. experienced a stock price increase of 3.32%, with a trading volume of 419 million yuan. The financing buy amount was 31.64 million yuan, while the financing repayment was 36.26 million yuan, resulting in a net financing outflow of 4.61 million yuan [1] - As of February 3, the total margin trading balance for Tongda Co., Ltd. was 278 million yuan, which represents 5.15% of its market capitalization. This financing balance is above the 80th percentile of the past year, indicating a high level of activity [1] - The company reported a revenue of 6.066 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 40.78%. The net profit attributable to shareholders was 132 million yuan, marking an 83.29% increase compared to the previous year [2] - The main business revenue composition includes aluminum plate and strip products (38.62%), ultra-high voltage cables (26.26%), and power cables (18.66%), among others [2] - As of September 30, 2025, the number of shareholders for Tongda Co., Ltd. was 56,800, a decrease of 21.93% from the previous period, while the average circulating shares per person increased by 28.09% to 7,968 shares [2] - The company has distributed a total of 256 million yuan in dividends since its A-share listing, with 52.38 million yuan distributed in the last three years [3] - New institutional shareholders include Guangfa Quantitative Multi-Factor Mixed A and other funds, indicating growing institutional interest in the company [3]

2月3日，明牌珠宝涨3.69%，成交额1.56亿元。两融数据显示，当日明牌珠宝获融资买入额1634.97万 元，融资偿还2818.84万元，融资净买入-1183.87万元。截至2月3日，明牌珠宝融资融券余额合计1.26亿 元。 融资方面，明牌珠宝当日融资买入1634.97万元。当前融资余额1.26亿元，占流通市值的3.68%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，明牌珠宝2月3日融券偿还1000.00股，融券卖出700.00股，按当日收盘价计算，卖出金额 4529.00元；融券余量4.41万股，融券余额28.53万元，超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，明牌珠宝十大流通股东中，黄金股ETF（517520）位居第七大流 通股东，持股304.30万股，相比上期增加137.55万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，浙江明牌珠宝股份 ...

Group 1 - The core viewpoint of the news is that Shandong Zhanggu has experienced fluctuations in stock performance and financial metrics, indicating potential investment opportunities and risks [1][2]. - On February 3, Shandong Zhanggu's stock rose by 3.58%, with a trading volume of 129 million yuan. The financing buy-in amount was 8.31 million yuan, while the financing repayment was 6.97 million yuan, resulting in a net financing buy of 1.34 million yuan [1]. - As of February 3, the total financing and securities lending balance for Shandong Zhanggu was 128 million yuan, with the financing balance accounting for 4.05% of the circulating market value, which is below the 20th percentile level over the past year [1]. Group 2 - As of January 30, the number of shareholders for Shandong Zhanggu was 37,800, a decrease of 5.09% from the previous period. The average circulating shares per person increased by 5.37% to 7,445 shares [2]. - For the period from January to September 2025, Shandong Zhanggu reported operating revenue of 1.46 billion yuan, a year-on-year decrease of 3.94%. The net profit attributable to the parent company was 61.96 million yuan, down 39.12% year-on-year [2]. - Since its A-share listing, Shandong Zhanggu has distributed a total of 590 million yuan in dividends, with 93.64 million yuan distributed over the past three years [3].

Core Viewpoint - Zhaoli Pharmaceutical has shown a mixed performance in financing activities and stockholder dynamics, with significant revenue growth and profit increase reported for the year 2025. Financing Activities - On February 3, Zhaoli Pharmaceutical's financing buy-in amounted to 18.73 million yuan, while financing repayment was 19.85 million yuan, resulting in a net financing outflow of 1.11 million yuan [1] - As of February 3, the total financing and securities balance for Zhaoli Pharmaceutical was 604 million yuan, with the financing balance accounting for 5.03% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending balance of 2.75 million yuan, with a lending volume of 162,000 shares, also reflecting a high level compared to the past year [1] Company Performance - For the period from January to September 2025, Zhaoli Pharmaceutical achieved an operating income of 2.28 billion yuan, representing a year-on-year growth of 11.48% [2] - The net profit attributable to the parent company for the same period was 510 million yuan, showing a year-on-year increase of 21.00% [2] Shareholder Dynamics - As of September 30, 2025, the number of shareholders for Zhaoli Pharmaceutical reached 41,400, an increase of 7.31% compared to the previous period [2] - The average circulating shares per person decreased by 6.82% to 14,562 shares [2] - The company has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed in the last three years [3]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Yingjixin Technology Co., Ltd., indicating a mixed sentiment in the market with a slight increase in stock price but a net outflow in financing [1] - On February 3, Yingjixin's stock rose by 3.61%, with a trading volume of 248 million yuan, while the financing buy-in amounted to 21.97 million yuan and financing repayment was 32.16 million yuan, resulting in a net financing outflow of 10.18 million yuan [1] - As of February 3, the total balance of margin trading for Yingjixin was 287 million yuan, which represents 2.61% of its circulating market value, indicating a high level of financing compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Yingjixin increased to 15,600, reflecting a growth of 13.58%, while the average circulating shares per person decreased by 11.95% to 19,194 shares [2] - For the period from January to September 2025, Yingjixin reported a revenue of 1.169 billion yuan, marking a year-on-year growth of 14.16%, and a net profit attributable to shareholders of 114 million yuan, which is a 28.54% increase compared to the previous year [2] - Since its A-share listing, Yingjixin has distributed a total of 171 million yuan in dividends, with 155 million yuan distributed over the last three years [2]

Group 1 - On February 3, Fu'an Pharmaceutical's stock increased by 1.37%, with a trading volume of 59.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 6.72 million yuan and a financing repayment of 8.12 million yuan, resulting in a net financing buy of -1.40 million yuan [1] - As of February 3, the total balance of margin trading for Fu'an Pharmaceutical was 360 million yuan, which is 6.83% of its circulating market value, indicating a low level compared to the past year [1] Group 2 - As of January 30, the number of shareholders for Fu'an Pharmaceutical was 39,100, an increase of 0.54% from the previous period, while the average circulating shares per person decreased by 0.53% to 24,795 shares [2] - For the period from January to September 2025, Fu'an Pharmaceutical reported an operating income of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit attributable to shareholders of 166 million yuan, down 44.87% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed in the last three years [2]

Core Viewpoint - Tongkun Co., Ltd. has shown fluctuations in stock performance and financing activities, with a notable decrease in shareholder numbers and a mixed financial performance in recent periods [1][2]. Group 1: Stock Performance and Financing - On February 3, Tongkun's stock rose by 4.48%, with a trading volume of 974 million yuan [1]. - The financing buy-in amount for Tongkun on the same day was 44.88 million yuan, while the financing repayment was 136 million yuan, resulting in a net financing outflow of 90.92 million yuan [1]. - As of February 3, the total financing and securities lending balance for Tongkun was 1.918 billion yuan, with the financing balance at 1.909 billion yuan, accounting for 3.80% of the circulating market value, which is below the 10% percentile level over the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Tongkun reported operating revenue of 67.397 billion yuan, a year-on-year decrease of 11.38%, while the net profit attributable to shareholders increased by 53.83% to 1.549 billion yuan [2]. - The company has cumulatively distributed dividends of 3.203 billion yuan since its A-share listing, with 341 million yuan distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Tongkun was 50,100, a decrease of 28.96% from the previous period, while the average circulating shares per person increased by 40.76% to 47,780 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fifth with 35.9221 million shares, an increase of 9.4667 million shares from the previous period [3].

Group 1 - BYD's stock price increased by 0.37% on February 3, with a trading volume of 3.276 billion yuan. The financing buy amount was 222 million yuan, while the financing repayment was 307 million yuan, resulting in a net financing buy of -84.82 million yuan. The total financing and securities balance reached 12.823 billion yuan [1] - As of February 3, BYD's financing balance was 12.771 billion yuan, accounting for 2.69% of its circulating market value, which is below the 50th percentile level over the past year, indicating a low position [1] - On the same day, BYD's securities lending saw a repayment of 34,600 shares and a sale of 32,900 shares, with a selling amount of 2.8745 million yuan. The remaining securities lending volume was 601,400 shares, with a balance of 52.5446 million yuan, exceeding the 70th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, BYD had 642,600 shareholders, an increase of 98.37% compared to the previous period. The average circulating shares per person were 5,427, an increase of 51.21% [2] - For the period from January to September 2025, BYD achieved an operating income of 566.266 billion yuan, a year-on-year increase of 12.75%. However, the net profit attributable to shareholders decreased by 7.55% to 23.333 billion yuan [2] - BYD has distributed a total of 27.859 billion yuan in dividends since its A-share listing, with 24.414 billion yuan distributed in the last three years [3]

双融日报 --鑫融讯 2026 年 02 月 04 日 市场情绪：71 分（较热） 2、银行主题：银行股具有高股息特性，如中证银行指数的股 息率高达 6.02%，显著高于 10 年期国债收益率。在经济增 速放缓和市场波动加大时，银行股凭借稳定的分红能力，成 为险资、社保等长期资金的重要配置标的。相关标的：农业 银行（601288）、宁波银行（002142） 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -10 -5 0 5 10 15 20 25 30 (%) 沪深300 相关研究 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 71 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1 ▌ 热点主题追踪 今日热点主题：电网设备、银行、消费 1、电网设备主题：全球 AI 数据中心（AIDC）耗电量巨大， 催生了对高功率、高稳定性变压器等核心电力设备的刚性需 求。目前全球供需严重失衡，美国市场交货周期已长达 127 周。与此同时，国内"十五五"期间，国家电网 4 万亿元的 巨 ...

2月3日，泰格医药涨4.97%，成交额10.32亿元。两融数据显示，当日泰格医药获融资买入额5393.21万 元，融资偿还5727.85万元，融资净买入-334.64万元。截至2月3日，泰格医药融资融券余额合计6.31亿 元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.45%。 分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少 ...